OBIO - NASDAQ

Orchestra BioMed Holdings, Inc.

OBIO·NASDAQ

$3.86

-0.52%

HealthcareBiotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$231.14M

EPS-1.1100

P/E Ratio-3.48

Earnings Date08/11/2026

obio

Sales/Maturities of Investments

Last Annual Value

49.86M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Orchestra BioMed Holdings, Inc. Competitors Analysis of Sales/Maturities of Investments

OBIO · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	49.86M	-31.2%	29.9%	N/A
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA	262.87M	-7.2%	-5.3%	5.5%
Avalo Therapeutics, Inc. NASDAQ:AVTX	31.31M	N/A	N/A	N/A
Invivyd, Inc. NASDAQ:IVVD	0.00	N/A	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	154.39M	-6.8%	N/A	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	252.83M	-9.2%	N/A	N/A
Codexis, Inc. NASDAQ:CDXS	85.13M	478.4%	N/A	170.9%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	161.46M	32.4%	63.4%	N/A
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	0.00	N/A	N/A	N/A
OmniAb, Inc. NASDAQ:OABI	50.89M	-20.2%	109.4%	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	0.00	N/A	N/A	N/A

Orchestra BioMed Holdings, Inc. Fair Value Envelope

OBIO · NASDAQ

Our analysis suggests that OBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.86, this represents a potential HIDDEN relative to our calculated worth for Orchestra BioMed Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.86

Related Guides

Blog Categories

Continue your OBIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.